Shuangdan Mingmu Capsule for Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 1

The characteristics of the included studies.

Reference	Design	Sample size (T/C)	Age (T/C)	Interventions (T/C)	Outcomes
Tu et al. 2009 [19]	RCT	102/100	1870	SDMMC + doxium/doxium	①②
Pang 2015 [18]	RCT	40/40	49.4 ± 5.7/49.6 ± 5.3	SDMMC + doxium/doxium	①
Jin and Zhang 2019 [17]	RCT	72/71	63.07 ± 8.08/62.39 ± 8.34	SDMMC + calcium dobesilate/calcium dobesilate	①②④⑤
Fu 2019 [15]	RCT	40/40	56.37 ± 11.21	SDMMC + calcium dobesilate/calcium dobesilate	③
Liu et al. 2019 [16]	RCT	60/60	57.54 ± 8.11/57.10 ± 9.26	SDMMC + calcium dobesilate/calcium dobesilate	①④⑤⑥⑦
Zhang et al. 2021 [14]	RCT	53/53	69.70 ± 2.12/69.70 ± 2.13	SDMMC + compound anisodine hydrobromide injection/compound anisodine hydrobromide injection	②
Ji and Liu 2022 [20]	RCT	52/52	56.63 ± 4.02/56.53 ± 4.09	SDMMC + calcium dobesilate/calcium dobesilate	①⑥⑦

Notes: ① clinical effective rate; ② eyesight; ③ blood glucose; ④ TCMsymptomscore; ⑤ CLVQOL scores; ⑥ macular thickness and hemorrhagic spot area; ⑦ vascular endothelial growth factor levels and platelet-derived growth factor levels RCT, randomized controlled trial; T/C, treatment group/control group.